Case Studies
Just a Few Examples of What We Can Do To Secure Funding for YOU
Each year, Grant Engine partners with over 200 companies, helping them secure non-dilutive funding from agencies like NIH, BARDA, ARPA-H, DoD, and numerous foundations. With win rates 2x to 4x the industry average, we’ve helped our clients secure hundreds of millions in funding. Here are just a few examples.
Captura BioPharma, a leader in developing medical countermeasures against radiological threats, had an ambitious goal to pursue $82 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to advance their groundbreaking project, all while maintaining equity: a monumental task that required both precision and strategic foresight. READ THIS CASE STUDY.
Reveal Biosciences had developed an advanced AI-driven pathology platform, but they faced the dual challenge of accelerating R&D while securing non-dilutive funding under very tight timelines. RevealBio’s leadership needed more than just funding. They needed a partner to translate their complex science into compelling narratives aligned with agency priorities, while ensuring that each submission demonstrated both feasibility and innovation. In part due to their 100% win grant rate, the company was successfully sold to CellCarta. READ THIS CASE STUDY.
Gilgamesh Pharmaceutical, a leader in the development of novel therapies for psychiatric and neurological conditions, secured a UG3/UH3 grant to propel its innovative research into new treatments for drug abuse and dependency. This grant was fully written and secured by Grant Engine. As a subsequent milestone of the company’s excellent progress, Gilgamesh entered into a transaction with AbbVie on Aug 25, 2025 for $1.2 billion to partner their bretisilocin program. READ THIS CASE STUDY.
Safe Health Systems (SHS) is a leader in digital healthcare innovation, needed to respond to a highly competitive funding opportunity with a short four-week deadline and little room for error. READ THIS CASE STUDY.
OncoNano Medicine, a pioneering company in the field of nanotechnology for cancer treatment, was at a critical juncture. They needed to secure funding to advance their innovative diagnostic and therapeutic solutions aimed at revolutionizing cancer care while complying with stringent NIH standards. READ THIS CASE STUDY.
